ZIMLAB2023-10-012023-12-31 ZIMLAB2023-10-012023-12-31 ZIMLAB2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member ZIMLAB2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member ZIMLAB2023-12-31 ZIMLAB2023-10-012023-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ZIMLAB2023-10-012023-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ZIMLAB2023-10-012023-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member ZIMLAB2023-10-012023-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 541400 ZIMLAB NA Zim Laboratories Limited Equity 2023-04-01 2024-03-31 2024-01-29 2024-01-22 INR Lakhs Third quarter 14:00:00 16:00:00 2024-01-29 2024-01-29 Not applicable Single segment Pharmaceutical Industry 2023-10-01 2023-12-31 Unaudited Consolidated 962926000.00 11123000.00 974049000.00 515089000.00 30065000.00 -102992000.00 131712000.00 16962000.00 39354000.00 273719000.00 903909000.00 70140000.00 0.00 70140000.00 13498000.00 8796000.00 22294000.00 0.00 47846000.00 0.00 0.00 0.00 0.00 47846000.00 -421000.00 47425000.00 47846000.00 0.00 47425000.00 0.00 487258000.00 10 0.98 0.98 0.00 0.00 0.98 0.98 0.00 0.02 0.05 Notes : 1) The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 29 January 2024. There are no qualifications in the limited review report issued for the quarter and nine months ended 31 December 2023. 2) These financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard ('Ind AS') notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended), as prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations and guidelines issued by the Securities and Exchange Board of India (SEBI). 3) The Company and its subsidiaries are principally engaged in a single business segment which is pharmaceuticals . 4) During the previous quarter, the wholly owned subsidiary 'Zim Laboratories FZE' of holding company has incorporated a subsidiary 'ZIM Laboratories Middle East DMCC ' in Dubai with effect from 28 September 2023. Place: Nagpur Anwar S. Daud Date: 29 January 2024 Managing Director Single segment 2023-04-01 2023-12-31 Unaudited Consolidated 2495616000.00 36492000.00 2532108000.00 1242125000.00 56778000.00 -146397000.00 386308000.00 46473000.00 120465000.00 699928000.00 2405680000.00 126428000.00 0.00 126428000.00 22288000.00 12533000.00 34821000.00 0.00 91607000.00 0.00 0.00 0.00 0.00 91607000.00 -1784000.00 89823000.00 91607000.00 0.00 89823000.00 0.00 487258000.00 10 1.88 1.88 0.00 0.00 1.88 1.88 0.00 0.02 0.04 Other Expenses 273719000.00 Other Expenses 699928000.00 Measurements of defined employee benefit plans -1628000.00 Measurements of defined employee benefit plans -4885000.00 -1628000.00 -4885000.00 -474000.00 -1422000.00 Gains and losses arising from translating the financial statements of foreign operation 733000.00 Gains and losses arising from translating the financial statements of foreign operation 1679000.00 733000.00 1679000.00 0.00 0.00